Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) FCF Margin (2022 - 2023)

Historic FCF Margin for Pasithea Therapeutics (KTTA) over the last 2 years, with Q2 2023 value amounting to 886.34%.

  • Pasithea Therapeutics' FCF Margin rose 134157400.0% to 886.34% in Q2 2023 from the same period last year, while for Mar 2024 it was 4000.3%, marking a year-over-year decrease of 8294400.0%. This contributed to the annual value of 2466.64% for FY2022, which is 187494100.0% up from last year.
  • Per Pasithea Therapeutics' latest filing, its FCF Margin stood at 886.34% for Q2 2023, which was up 134157400.0% from 5459.15% recorded in Q1 2023.
  • Over the past 5 years, Pasithea Therapeutics' FCF Margin peaked at 5459.15% during Q1 2023, and registered a low of 15771.77% during Q1 2022.